BioMarin shares gain momentum as Jefferies raises price target to $105
AI Summary- Jefferies raised its price target for BioMarin Pharmaceutical Inc.
- $105 became Jefferies' new price target for BioMarin.
- BioMarin secured new revenue streams through a patent settlement with Ascendis Pharma.